EHA 2024 Hybrid Congress
Heme Today is at the European Hematology Association 2024 Hybrid Congress, hosted June 13-16, 2024 in Madrid, Spain. We are covering EHA 2024 as it showcases the latest scientific research in hematologic malignancies and their clinical management.
Mairéad Ní Chonghaile, RGN, BNS, MSc, speaks on the need for training and support networks in this area of care.
Phase II study data demonstrate this benefit in patients with low-risk myeloid malignancies or precursor conditions.
Final data from a phase II trial suggest a promising option for elderly patients with this serious disease.
Results from a new analysis further support the initial findings of the global, phase III IMerge trial.
An ongoing phase IIA study reports safety and dosing data for patients with transfusion-dependent disease.
A retrospective observational study's clearest takeaway was that the agent can reduce spontaneous bleeding in severe disease.
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
This noninvasive technique is a potential improvement over bone marrow aspiration in MDS clinical evaluation and monitoring.
Advertisement
Advertisement
